×
About 17,373 results

A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
https://clinicaltrials.gov/ct2/show/NCT02685098

Sep 30th, 2022 - This is a phase I single center open label trial study that will enroll twenty-six (26) patients requiring semi-elective lower extremity major amputation within a 30 day period for non-infectious complications related to critical limb ischemia (CLI). After enrollment patients will be scheduled for amputation 7 days after MSC administration. The investigational treatment uses allogeneic bone mar...

Clinical Study of Focal Implant Used for Lower Extremity Post-angioplasty Dissection
https://clinicaltrials.gov/ct2/show/NCT05562076

Sep 30th, 2022 - This is a prospective, multicenter, randomized controlled trail using spot stenting to treat lower extremity post-angioplasty dissection.

Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA)
https://clinicaltrials.gov/ct2/show/NCT02863926

Sep 30th, 2022 - Patients scheduled for amputation will receive bone marrow cells concentrated via the MarrowStim device (cBMA) injected IM at 25 sites in the leg proximal to the amputation in the index limb to prevent ischemic wound complications after surgery. cBMA will be injected into the anterior tibialis muscle below the point of amputation in an area approximately 3cm^2 x 2cm^2 for analytical purposes. P...

Detour2 Continued Access Study
https://clinicaltrials.gov/ct2/show/NCT04625660

Sep 30th, 2022 - Prospective, single-arm, multi-center, clinical investigation to continue to evaluate the safety and effectiveness of the PQ Bypass System to access, deliver guidewires, and implant stent grafts for a percutaneous femoropopliteal (fem-pop) bypass.

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
https://clinicaltrials.gov/ct2/show/NCT04674969

Sep 30th, 2022 - A global prospective, non-randomized, open-label, multi-center Registry to collect Real-World Data, including health economic data, to support the use of commercially available drug-eluting BSC devices for the treatment of lesions located in the peripheral vasculature.

ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent
https://clinicaltrials.gov/ct2/show/NCT02574481

Sep 30th, 2022 - Atherosclerosis is a systemic disease that has become increasingly recognized in the expanding elderly population as a significant cause of morbidity and mortality. Atherosclerosis in the vessels of the lower extremities can cause a variety of symptoms ranging from intermittent claudication to ischemic rest pain and critical ischemia with major tissue loss. Typically, femoropopliteal lesions ha...

CAPTURER PMCF Study ( rEPIC04D )
https://clinicaltrials.gov/ct2/show/NCT05292079

Sep 30th, 2022 - The objective of this multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study is to confirm and support the clinical safety and performance of the CAPTURER in a NON-SELECTED, Real World population under daily clinical practice when used as intended by the manufacturer to meet EU Medical Device regulation requirements for post-market clinical follow-up.

STEPUP Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT05445375

Sep 30th, 2022 - This study will test whether, among patients undergoing surgery for peripheral artery disease (PAD), the addition of an online multimedia patient education video to the current education regimen will improve PAD knowledge, activation, and self-care engagement. The study will randomize 150 participants to one of 2 groups: current education regimen vs. current education regiment with video. The p...

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE)
https://clinicaltrials.gov/ct2/show/NCT05440422

Sep 30th, 2022 - Study Description: This is a double blind placebo-controlled study to characterize whether blocking type I IFN receptor signaling with anifrolumab will lead to improvements in vascular function, decreases in vascular inflammation and modulation of biomarkers of vascular risk in patients with systemic lupus erythematosus (SLE). Objectives: Primary Objective: To assess the role of anifrolumab in ...

Ketorolac-an Option for Post Operative Pain Management After Elective Cardiac Surgery.
https://clinicaltrials.gov/ct2/show/NCT05361824

Sep 30th, 2022 - DATA COLLECTION: Computer randomization was done for the numbers 1 to 60, having 50% probability of being in either of two groups: Ketorolac (treatment) or Paracetamol (control). After randomizing each number into either group, which ever patient (consenting and meeting the inclusion criteria) came, was allotted these numbers consecutively, as they presented for elective cardiac surgery. Thus r...

Association of PeRiODontal Disease and gUt Microbiome With Coronary artEry Disease (PRODUCE Study)
https://clinicaltrials.gov/ct2/show/NCT05560087

Sep 29th, 2022 - The previous studies have reported the associations among cardiovascular disease, periodontitis, and gut microbiome dysbiosis. However, there is a lack of evidences about the axis of association from oral-gut-cardiovascular disease. The investigators hypothesized that periodontal disease might induce dysbiosis of gut microbiome and dysbiosis might have a role in cardiovascular disease (as calle...

SCOPE-CLI: Shifting Care and Outcomes for Patients With Endangered Limbs
https://clinicaltrials.gov/ct2/show/NCT04710563

Sep 29th, 2022 - An estimated 8 million individuals in America are affected by peripheral arterial disease (PAD). One of its extreme expressions is Critical Limb Ischemia (CLI). It is one of the most severe vascular conditions associated with devastating outcomes, including poorly healing wounds, extreme pain, and a high amputation risk. It is also one of the deadliest conditions, with 6-month and 5-year mortal...

A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)
https://clinicaltrials.gov/ct2/show/NCT05378529

Sep 29th, 2022 - The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold: Evaluate the distribution of Lp(a) value in the overall participants with documented history of ASCVD Evaluate the distribution of Lp(a) value in participants with documented history of ASCVD by demographics ...

Compressive Elastic Dressing Versus TR Band
https://clinicaltrials.gov/ct2/show/NCT05409716

Sep 29th, 2022 - Radial approach is widely established in cardiac diagnostic and therapeutic treatments. It has been shown to decrease bleeding, vascular problems, and mortality rates when compared to the femoral approach. It also offers better comfort to patients through early mobility and lowers hospital expenses. Previously, there were no specific devices for radial artery hemostasis. Many different types of...

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non...
https://clinicaltrials.gov/ct2/show/NCT05360446

Sep 29th, 2022 - The purpose of this study is to evaluate the efficacy of inclisiran compared to placebo on top of maximally tolerated statin therapy in reducing total coronary atheroma volume assessed by coronary computed tomography angiography from baseline to month 24 in participants with a diagnosis of NOCAD without previous cardiovascular events, a CT-adapted Leaman score >5 and a FFRct >0.8. Participants ...

Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting
https://clinicaltrials.gov/ct2/show/NCT05380063

Sep 29th, 2022 - After informed consent, at least 10 centers and 2,300 eligible admissions will be recruited. Eligible patients would be randomized (1:1) in double-blind manner (patients and treating physicians) to dual antiplatelet therapy (DAPT) group (ticagrelor 90mg bid and aspirin 100 mg qd for 12 month) and de-escalated DAPT (De-DAPT) group (90mg bid and aspirin 100 mg qd for first 3 months, and then aspi...

Dual-antiplatelet Therapy Strategies for Elective PCI in a Real-world Setting
https://clinicaltrials.gov/ct2/show/NCT05559918

Sep 29th, 2022 - To assess the safety and efficacy of in-laboratory clopidogrel loading dose administration before ad-hoc PCI versus clopidogrel preloading treatment in patients planned for diagnostic angiography with optional ad-hoc PCI.

Comparison of Results Achieved by Different Ballooning Techniques in Bifurcation Stenting
https://clinicaltrials.gov/ct2/show/NCT05559424

Sep 29th, 2022 - A preclinical phase of the study (CRABBS-VHL) was performed in isolated porcine hearts comparing the two common side-branch (SB) optimization techniques after stent implantation in the main vessel (MV): proximal optimization technique (POT) + kissing balloon inflation + final POT (PKP arm) and POT + isolated balloon inflation + final POT (PSP arm). A total of 30 PCIs were successfully performed...

Distal Evaluation of Functional Performance With Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting
https://clinicaltrials.gov/ct2/show/NCT04451044

Sep 28th, 2022 - Multi-center, prospective, randomized controlled study comparing PCI guided by angiography versus iFR Co-Registration using commercially available Philips pressure guidewires and the SyncVision co-registration system, employing an adaptive design study for interim sample size re-estimation.

Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk
https://clinicaltrials.gov/ct2/show/NCT04753372

Sep 28th, 2022 - This study is a national multicentre (~15 sites), prospective, single-arm, observational study in patients treated with rivaroxaban 2.5mg bid on top of ASA75-100mg OD (N=1000). Female and male patients with a diagnosis of CCS and/or symptomatic PAD will be enrolled in the (outpatient) clinic after the decision for treatment with rivaroxaban 2.5mg bid, co-administered with acetylsalicylic acid h...